In 1997, Philippe Chauveau was named chairman of EDAP-TMS S.A. Supervisory Board, involving a two-tier board structure overseeing an Executive Board. In 2002, both these boards were replaced by a single Board of Directors, which Philippe Chauveau headed as Chairman and CEO. While remaining Chairman of the Board, he was succeeded by Hugues de Bantel, as CEO, in 2004. Philippe Chauveau, since 2000, is also Chairman of the Board of SCYNEXIS Inc., funded by private equity, which is an innovative drug discovery company, based in the USA, partnering with major pharmaceutical companies worldwide. He is also personal executive coach to senior research leaders at HOFFMANN LaROCHE in Switzerland. He was R&D Vice-President at AT&T BELL LABS; he had been Chairman of APPLE COMPUTER Europe, preceded by increasing marketing roles in ITT and in PROCTER & GAMBLE. Philippe Chauveau has a French, Anglo-Irish and American education and
culture. He has an Honours Degree from Trinity College Dublin with a BA., and a Bsc.
Pierre Beysson was elected as a member of the Board of Directors in September 2008. Pierre Beysson was then the Chief Financial Officer of Compagnie des Wagons-Lits ("CWC"), the on-board train service division of Accor, a French multinational Hotel and Business Services Group. In this capacity he sat in a number of boards of companies related to the Accor Group. He is now an M&A consultant. Prior to his assignment at CWL, Pierre Beysson has held a number of senior financial positions with Nixdorf Computers, Trane (Air Conditioning), AM International (Office Equipment) and FMC (Petroleum Equipment). His background also includes Industrial Project & Distribution Network Management with Computervision (Computed Aided
Design) and Customer Service & Distribution Network Management with Siemens-Nixdorf International. Pierre Beysson was trained as a CPA, has auditing experience and holds an MBA from Havard Business School.
Mr. Michiels is a 30-year U.S. veteran of the medical device industry. He most recently served as chief operating officer (COO) of CoreValve; and President and COO of InterVentional Technologies. He helped drive both companies from cardiovascular start-ups to established market leaders, using new and innovative technologies which have strong synergies to the HIFU story. Michiels is a founding partner of CONSILIUM, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch languages, he holds a bachelor's degree in economics from Antwerp University in Belgium and a Masters in business administration (MBA) from Indiana University.
Dr. Argil Wheelock was elected as a member of the Company's Board of Directors in June 2009. Dr. Wheelock, a U.S. board certified urologist, is currently Chief of Urology at Erlanger Medical Center, a tertiary care and teaching hospital in Chattanooga, Tennessee. He is a director and Chief Medical Advisor to HealthTronics Inc., a leading U.S. provider of urological services and products. From 1996 to 2005, Dr. Wheelock served as Chairman and CEO of HealthTronics, a publicly traded NASDAQ company where he was a founder. He has built a successful track record introducing new medical devices to the U.S. and navigating the FDA approval process. He is widely known among the U.S. urological community for bringing clinical benefits to patients and economic value to urology practices. Dr. Wheelock graduated from the University of Tennessee College of Medicine and completed urological training at Mount Sinai Hospital in New York City.
= Chair
= Member
= Independent Director
